Reference data
A practical, source-backed reference for people tracking the U.S. medical device development landscape. Every figure below links to its primary FDA source and states the reporting period it represents.
Last updated October 9, 2026
Read the numbers carefully
A statistic can clarify the scale of a system, but it cannot determine the right development path for a specific technology. Product design, intended use, risk, evidence, clinical context, quality priorities, and the state of the venture all shape the questions a team needs to answer.
This page gathers a small set of figures that are straightforward to cite, then preserves the source and reporting date beside each one. It is designed as a starting point for writers, collaborators, and early teams who need an accurate orientation to the U.S. device landscape.
FDA figures at a glance
FDA’s Center for Devices and Radiological Health granted this many Breakthrough Device designations in 2024. A designation is not a marketing authorization, but it can create an expedited review pathway for qualifying technologies.
Source: FDA CDRH 2024 Annual Report Reporting period: 2024FDA reported 42 marketing authorizations for Breakthrough Devices in 2024, across the applicable premarket pathways.
Source: FDA CDRH 2024 Annual Report Reporting period: 2024FDA’s voluntary Safer Technologies Program enrolled 17 devices in 2024. The program is intended for certain devices that may meaningfully improve the safety of currently available treatments or diagnostics.
Source: FDA CDRH 2024 Annual Report Reporting period: 2024CDRH received 3,555 510(k) submissions in fiscal year 2024, excluding third-party submissions. A 510(k) is one FDA premarket route, not a universal measure of medical device innovation.
Source: FDA, CDRH 510(k)s, FY 2024 Reporting period: FY 2024Of the fiscal-year 2024 submissions in FDA’s status report, 3,461 had been accepted as of September 30, 2025. The later date matters because submission status can change after the fiscal year closes.
Source: FDA, CDRH 510(k)s, FY 2024 Reporting period: As of September 30, 2025The FDA’s downloadable MAUDE file for 2024 contains this many device-data records. These are records associated with reported events, not confirmed incident rates or a count of unique patients or devices.
Source: FDA MDR Data Files Reporting period: Calendar year 2024What the pathways mean
FDA describes the 510(k) process as a premarket submission used to show substantial equivalence to a legally marketed device. Premarket approval is a separate, more stringent application that requires valid scientific evidence supporting reasonable assurance of safety and effectiveness for the intended use. The De Novo route can classify certain novel low- to moderate-risk devices.
That distinction is why submission totals should not be treated as odds of success, timelines, or a recommendation for any individual product. A careful development plan connects the regulatory question with the product, evidence, clinical programs, quality assurance, business plan, team, and financing decisions around it.
Read FDA’s pathway overviewMethod and sources
The figures above are taken from FDA publications and downloadable FDA data references. They are presented as reported by the FDA, without combining separate datasets or calculating rates. The most recent primary source available for each figure is linked directly from the statistic.
Nexus Life Sciences. Medical Device Development Statistics: FDA 2024. Updated October 9, 2026. https://medtech-startup.com/medical-device-development-statistics
This reference page is updated on a regular review cycle. Source links and reporting dates are retained so a reader can check the original data before relying on it.
Bring the program into focus